Get informed when a big investor buys or sells
+ FollowUndervalued by 2401.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $27,153.00 |
|---|---|
| Enterprise Value | $-538,832.00 |
| Earnings per Share | $-3.45 |
| Beta | 0.47 |
| Outstanding Shares | 1,810,208 |
| P/E Ratio | 0.24 |
|---|---|
| PEG | -0.3 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 10.50%▼ 0.32% |
|---|---|
| Total Invested | $5,468▲ 6.80% |
| Investors Holding | 3▼ 1.00% |
Protagenic Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorder...
Stockcircle shows 7 open-market insider purchases for Protagenic Therapeutics- Warrants (13/04/2025) in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.